What a bode of confidence from the Nicoya CEO! Particularly the last 3 words.
Nicoya CEO and Founder Ryan Denomme said: “While Alto is a critical tool in drug development with its unprecedented sample throughput and automation capabilities, it’s also broadly applicable in many other impactful areas of disease research that align with our mission to improve human life.
There is significant potential to leverage the Alto platform as a clinical diagnostic tool for many diseases, including cancer detection. We are excited to partner with INOVIQ in the development of this novel in‐vitro diagnostic test and bring together our unique technologies to commercialize this life‐changing innovation.”
Good luck to all shareholders and hopefully sufferers in the not-too-distant future can have a fighting chance with this early detection.
- Forums
- ASX - By Stock
- Ann: INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform
What a bode of confidence from the Nicoya CEO! Particularly the...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
(20min delay)
|
|||||
Last
59.0¢ |
Change
-0.010(1.67%) |
Mkt cap ! $65.06M |
Open | High | Low | Value | Volume |
60.0¢ | 60.0¢ | 59.0¢ | $17.47K | 29.17K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 41547 | 58.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
61.0¢ | 13799 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 41547 | 0.585 |
1 | 2269 | 0.580 |
1 | 5000 | 0.575 |
3 | 25481 | 0.565 |
3 | 28887 | 0.560 |
Price($) | Vol. | No. |
---|---|---|
0.610 | 13799 | 4 |
0.620 | 19392 | 3 |
0.625 | 1584 | 1 |
0.630 | 12205 | 2 |
0.650 | 4750 | 1 |
Last trade - 15.51pm 26/07/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |